Assetmark, Inc Galapagos Nv Transaction History

Assetmark, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$47.03 - $57.12 $8,042 - $9,767	-171 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$68.86 - $83.34 $44,139 - $53,420	-641 Reduced 78.94%	171 $12,000
Q1 2021 May 14, 2021	SELL	$76.15 - $111.94 $193,344 - $284,215	-2,539 Reduced 75.77%	812 $63,000
Q4 2020 Feb 10, 2021	SELL	$96.85 - $148.25 $333,841 - $511,017	-3,447 Reduced 50.71%	3,351 $332,000
Q3 2020 Nov 13, 2020	BUY	$122.47 - $213.56 $110,467 - $192,631	902 Added 15.3%	6,798 $965,000
Q2 2020 Aug 11, 2020	BUY	$185.52 - $231.25 $84,040 - $104,756	453 Added 8.32%	5,896 $1.16 Million
Q1 2020 May 12, 2020	BUY	$143.0 - $274.03 $762,905 - $1.46 Million	5,335 Added 4939.81%	5,443 $1.07 Million
Q4 2019 Feb 11, 2020	SELL	$146.12 - $215.82 $2,045 - $3,021	-14 Reduced 11.48%	108 $22,000
Q3 2019 Nov 13, 2019	BUY	$130.44 - $187.64 $15,913 - $22,892	122 New	122 $19,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.